CureDuchenne Shares Updates from 29th Annual Congress of the World Muscle Society We’re at the 29th Annual Congress of the World Muscle Society this week and are pleased to share […]
As an early investor in Capricor Therapeutics, CureDuchenne is happy to share that Capricor has announced their intent to apply to the FDA for full approval of Deramiocel (CAP-1002) for […]
CureDuchenne is pleased to communicate that Wave Life Sciences announced positive interim data from the ongoing Phase 2 FORWARD-53 study in Duchenne amenable skipping exon 53. After 24 weeks of […]
SEE THE FULL PRESS RELEASE BELOW AND HERE – Second annual DREAMS Grant Program awards $25,000 each to three U.S.-based non-profit organizations working to achieve greater equality for those living […]
CureDuchenne welcomes the recent initiative the Food and Drug Administration (FDA) has taken to improve efficiencies in drug development, manufacturing, and the review process for new drug applications that incorporate […]
As an early investor in Dyne Therapeutics, CureDuchenne is pleased share that Dyne announced positive data from their Phase 1/2 trial of DYNE-251 in individuals with Duchenne amenable to skipping […]
In a promising development, the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (ACHNDC) has advanced the nomination of Duchenne muscular dystrophy (DMD) for inclusion in the Recommended Uniform Screening Panel (RUSP), a list of disorders that are screened for at birth.
Dallas’ Finest Will Unite to Advance Innovative Research and Care for Duchenne Muscular Dystrophy Dallas, TX – August 19, 2024– CureDuchenne, a leading nonprofit dedicated to finding a cure for […]
Newport Beach, CA – August 15, 2024 — CureDuchenne, a global leader in research, patient care and innovation for improving and extending the lives of those with Duchenne muscular dystrophy, […]
